hCAI/II-IN-6 is an orally active human carbonic anhydrase (CA) inhibitor. hCAI/II-IN-6 selectively inhibits hCA II and hCA VII isoforms with Ki values of 220, 4.9, 6.5 and ＞50000 nM for hCA I, hCA II , hCA VII and hCA XII respectively. hCAI/II-IN-6 shows anticonvulsant activity and anti maximal electroshock (MES) activity in vivo. hCAI/II-IN-6 can be used for the research of epilepsy[1].
hCAI/II-IN-6 (0-50 μM) inhibits hCA I, hCA II , hCA VII and hCA XII activities with Ki values of 220, 4.9, 6.5 and ＞50000 nM, respectively[1].
hCAI/II-IN-6 (30-100mg/kg; i.p. once) shows good anticonvulsant effect in vivo[1].
hCAI/II-IN-6 (30 mg/kg; p.o. once) shows anti-MES activity in vivo[1].
| Animal Model: | Swiss albino mice[1] |
| Dosage: | 30 and 100 mg/kg |
| Administration: | Intraperitoneal injection; 30-100 mg/kg once |
| Result: | Provided seizure attenuation and good anticonvulsant effect, and showed an ED50 of 13.7mg/kg in anticonvulsant quantification study. |
| Animal Model: | Wistar albino rats[1] |
| Dosage: | 30 mg/kg |
| Administration: | Oral gavage; 30 mg/kg once |
| Result: | Showed anti-MES activity and significant protection from seizures up to 1h of drug administration and action was gone reduced after 1h. |